Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Past history

<< Previous

Bullboard Posts

Next >>

Comment by pricelesson Dec 09, 2020 1:32pm

196 Views

Post# 32068740

RE:Past history

Yes past AGM have given shareholders little to look forward other than future financing to continue trials yet Donny always aludes to BP discussion going well and moving forward. The old broken record... Well maybe this one time shareholder will be shocked with a NR and a deal, Oristar obviously believes a deal is ether really close or in hand so maybe we'll ahve a merry Christmas after all!!

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price